Lacave, F.; de Terwangne, C.; Darius, T.; Buemi, A.; Mourad, M.; France, Y.; Cardoso Coelho, J.; Fernandes, G.; Goffin, E.; Devresse, A.;
et al. Basiliximab vs. No Induction Therapy in Kidney Transplant Recipients with a Low Immunological Risk Profile Receiving Tacrolimus/Mycophenolate/Steroids Maintenance Immunosuppression. J. Clin. Med. 2024, 13, 6151.
https://doi.org/10.3390/jcm13206151
AMA Style
Lacave F, de Terwangne C, Darius T, Buemi A, Mourad M, France Y, Cardoso Coelho J, Fernandes G, Goffin E, Devresse A,
et al. Basiliximab vs. No Induction Therapy in Kidney Transplant Recipients with a Low Immunological Risk Profile Receiving Tacrolimus/Mycophenolate/Steroids Maintenance Immunosuppression. Journal of Clinical Medicine. 2024; 13(20):6151.
https://doi.org/10.3390/jcm13206151
Chicago/Turabian Style
Lacave, Florian, Christophe de Terwangne, Tom Darius, Antoine Buemi, Michel Mourad, Yannick France, Joana Cardoso Coelho, Guillaume Fernandes, Eric Goffin, Arnaud Devresse,
and et al. 2024. "Basiliximab vs. No Induction Therapy in Kidney Transplant Recipients with a Low Immunological Risk Profile Receiving Tacrolimus/Mycophenolate/Steroids Maintenance Immunosuppression" Journal of Clinical Medicine 13, no. 20: 6151.
https://doi.org/10.3390/jcm13206151
APA Style
Lacave, F., de Terwangne, C., Darius, T., Buemi, A., Mourad, M., France, Y., Cardoso Coelho, J., Fernandes, G., Goffin, E., Devresse, A., & Kanaan, N.
(2024). Basiliximab vs. No Induction Therapy in Kidney Transplant Recipients with a Low Immunological Risk Profile Receiving Tacrolimus/Mycophenolate/Steroids Maintenance Immunosuppression. Journal of Clinical Medicine, 13(20), 6151.
https://doi.org/10.3390/jcm13206151
